Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Chatelut

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokineticsC Terret, E Erdociain, R Guimbaud, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapyH Rubie, F Doz, G Vassal, et al.
Clinical Pharmacology and Therapeutics|August 13, 2015
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratioF Thomas, I Hennebelle, C Delmas, et al.
British Journal of Cancer|September 18, 2008
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsE Rouits, V Charasson, A Pétain, et al.
British Journal of Cancer|March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumoursJ P Delord, J Y Pierga, V Dieras, et al.
Journal of Medical Virology|January 26, 2011
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapyF Nicot, L Alric, K Barange, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokineticsC Terret, E Erdociain, R Guimbaud, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapyH Rubie, F Doz, G Vassal, et al.
Clinical Pharmacology and Therapeutics|August 13, 2015
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratioF Thomas, I Hennebelle, C Delmas, et al.
British Journal of Cancer|September 18, 2008
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsE Rouits, V Charasson, A Pétain, et al.
British Journal of Cancer|March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumoursJ P Delord, J Y Pierga, V Dieras, et al.
Journal of Medical Virology|January 26, 2011
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapyF Nicot, L Alric, K Barange, et al.
Pageof 8